Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, December 19, 2024

Comparative Efficacy of Neuroprotective Agents for Improving Neurological Function and Prognosis in Acute Ischemic Stroke: A Network Meta-Analysis

 First of all, stop using the term, neuroprotection! Neuronal cascade of death is the correct term! It gives absolutely NO SENSE OF URGENCY! If you tell your patients, you know nothing about stopping  the 5 causes of the neuronal cascade of death in the first week thus letting die hundreds of millions to billions of neurons.  They might just get angry with your incompetence!

Send me hate mail on this: oc1dean@gmail.com. I'll print your complete statement with your name and my response in my blog. Or are you afraid to engage with my stroke-addled mind? I would like to know why you aren't solving stroke to 100% recovery, because this doesn't solve stroke recovery at all!

You'll have to ask your competent? doctor why the hell edaravone is approved in Japan since 2001 but not the US.

Has your stroke hospital done anything with any of these in the last decade? OR ARE THEY COMPLETELY FUCKING INCOMPENT AT EVERYTHING IN STROKE? 

 You can easily see how much research is out there to be implemented and your hospital is totally incompetent if not done. 

  • dl-NBP (1 post to April 2017)

  • NA-1 (5 posts to October 2012) 

Comparative Efficacy of Neuroprotective Agents for Improving Neurological Function and Prognosis in Acute Ischemic Stroke: A Network Meta-Analysis

Yuchen Wang Yuchen Wang 1,2Mengqi Li Mengqi Li 1,2Yuye Jiang Yuye Jiang 1,2Qiuhong JI Qiuhong JI 1*
  • 1 Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
  • 2 School of Medicine, Nantong University, Nantong, Jiangsu Province, China

The final, formatted version of the article will be published soon.

You don't have a Frontiers account ? You can register here

cause of combined disability and mortality globally. While reperfusion therapies play a critical role in the management of acute ischemic stroke (AIS), their applicability is limited, leaving many patients with significant neurological deficits and poor prognoses.Neuroprotective agents have garnered attention for their potential as adjunct therapies; however, their relative efficacy remains unclear. This study utilized a network metaanalysis (NMA) to systematically compare the efficacy of neuroprotective agents in improving neurological function and prognosis in stroke patients. Methods: This study adhered to PRISMA guidelines and the Cochrane Handbook for systematic reviews. Randomized controlled trials (RCTs) were identified through comprehensive searches of the PubMed, Embase, and Cochrane Library databases. Two independent reviewers conducted the selection process, data extraction, and quality assessment. Outcomes included 90-day modified Rankin Scale(90d-mRS)、change of National Institutes of Health Stroke Scale score from baseline to 90-day/14-day/7-day (90day/14d/7d-NIHSS) and 90-day/14-day Barthel Index (90d/14d-BI).Data analyses were performed using RevMan 5.4 and Stata 14.0. Results: A total of 42 RCTs involving 12,210 participants were included in this analysis. The interventions assessed included Cerebrolysin, Citicoline, Edaravone, Edaravone Dextranol, HUK, Minocycline, NA-1, NBP, Vinpocetine, and Control. The NMA results demonstrated that NBP ranked highest for the 90d-mRS, 90d-NIHSS, 14d-NIHSS, and 14d-BI outcomes. Edaravone was found to be the most effective intervention for the 7d-NIHSS and 90d-BI outcomes.The findings of this study indicate that different neuroprotective agents exhibit distinct advantages at specific stages of recovery. NBP showed outstanding performance in improving 90d-mRS and 90d-NIHSS, underscoring its potential in long-term rehabilitation. Edaravone demonstrated significant superiority in 7d-NIHSS scores, highlighting its role in early neuroprotection. These results provide valuable insights for individualized clinical treatment. To further validate the efficacy and safety of neuroprotective agents, future studies should involve larger sample sizes and conduct multicenter, large-scale randomized controlled trials.

Keywords: Neuroprotective Agents, Network meta-analysis, n-Butylphthalide, Edaravone, Neurological function, stroke rehabilitation

Received: 19 Nov 2024; Accepted: 13 Dec 2024.

Copyright: © 2024 Wang, Li, Jiang and JI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.   

Posted by at
Labels: , , , , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)